30
Participants
Start Date
October 1, 2021
Primary Completion Date
November 17, 2024
Study Completion Date
November 17, 2024
CAV regimen bridging to HSCT
The enrolled patients will be firstly given CAV bridging regimen (cladribine 5mg/m2/ day for 5 days, cytarabine 20mg q12h for 10 days, and began at 100 mg on day 1 and increased stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, and 400 mg) on days 1-21. Conditioning regimen for allo-HSCT may be administrated after completion of the CAV regimen, with or without consolidation therapy.
The First Affiliated Hospital of Soochow University, Suzhou
The Second People's Hospital of Huai'an
OTHER
The First Affiliated Hospital of Soochow University
OTHER